Genelux Corp. (GNLX)
2.56
+0.04
(+1.59%)
USD |
NASDAQ |
Oct 02, 16:00
2.56
0.00 (0.00%)
Pre-Market: 20:00
Genelux Total Liabilities (Quarterly) : 10.09M for June 30, 2026
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 10.09M |
| March 31, 2026 | 9.451M |
| December 31, 2025 | 7.483M |
| September 30, 2025 | 6.396M |
| June 30, 2025 | 8.349M |
| March 31, 2025 | 9.139M |
| December 31, 2024 | 8.442M |
| September 30, 2024 | 7.179M |
| June 30, 2024 | 7.51M |
| March 31, 2024 | 9.592M |
| December 31, 2023 | 8.42M |
| Date | Value |
|---|---|
| September 30, 2023 | 10.04M |
| June 30, 2023 | 9.107M |
| March 31, 2023 | 11.92M |
| December 31, 2022 | 41.31M |
| September 30, 2022 | 38.52M |
| June 30, 2022 | 48.19M |
| March 31, 2022 | 46.74M |
| December 31, 2021 | 41.24M |
| September 30, 2021 | |
| June 30, 2021 | |
| March 31, 2021 | 35.85M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| Arcutis Biotherapeutics, Inc. | 267.96M |
| ACADIA Pharmaceuticals, Inc. | 436.29M |
| Alnylam Pharmaceuticals, Inc. | 4.205B |
| Savara, Inc. | 48.48M |
| Vericel Corp. | 132.82M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 26.20M |
| Shareholders Equity (Quarterly) | 16.11M |
| Debt to Equity Ratio | 0.1502 |
| Current Ratio | 2.394 |
| Net Debt Paydown Yield | -0.09% |